Paid Clinical Trials for Clinical Stage IV Cutaneous Melanoma AJCC v8

Showing all 13 results

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

in Locally Advanced Lung Non-Small Cell Carcinoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Bladder Carcinoma, Clinical Stage IV Cutaneous Melanoma AJCC v8

Other

Texas

Deadline:

12/31/2027

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

by CTG

in Unresectable Melanoma, Recurrent Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma

Other

Alabama

Deadline:

09/11/2026

Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain

by CTG

in Pathologic Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma

Other

Ohio

Deadline:

04/15/2026

Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

by CTG

in Clinical Stage IV Cutaneous Melanoma AJCC v8, Advanced Acral Melanoma, Metastatic Acral Melanoma, Advanced Mucosal Melanoma, Advanced Cutaneous Melanoma

Other

Georgia

Deadline:

12/31/2027

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

by CTG

in Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8, Locally Recurrent Head and Neck Squamous Cell Carcinoma

Other

Arizona

Deadline:

01/01/2027

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

by CTG

in Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8

Other

Texas

Deadline:

02/02/2027

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

by CTG

in Metastatic Mucosal Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma

Other

Georgia

Deadline:

03/06/2027

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

by CTG

in Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Advanced Melanoma

Other

Alabama

Deadline:

08/29/2026

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

by CTG

in Acral Lentiginous Melanoma, Mucosal Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8

Other

Alabama

Deadline:

10/30/2026

Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma

by CTG

in Clinical Stage III Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Mucosal Melanoma, Metastatic Choroid Melanoma

Other

Florida

Deadline:

01/20/2027

Effect of Diet on the Immune System in Patients With Stage III-IV Melanoma Receiving Immunotherapy, DIET Study

by CTG

in Metastatic Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8

Other

Texas

Deadline:

02/28/2026

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer

by CTG

in Metastatic Conjunctival Melanoma, Metastatic Acral Lentiginous Melanoma, Locally Advanced Cutaneous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8

Other

Washington

Deadline:

11/01/2026

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

by CTG

in Metastatic Digestive System Carcinoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma

Other

Arizona

Deadline:

06/30/2033

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain

Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma

Effect of Diet on the Immune System in Patients With Stage III-IV Melanoma Receiving Immunotherapy, DIET Study

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

Follow us on social media:

Participants

Organizations

Products

About Us

Mobile Apps

Get new clinical trials sent to you?

Paid Clinical Trials for Clinical Stage IV Cutaneous Melanoma AJCC v8

Filter Results:

Follow us on social media:

Participants

Organizations

Products

About Us

Mobile Apps